Answers are grounded in this paper and cite their sources.
Conference review highlights refined risk models and circulating tumor cells in light chain amyloidosis, indicating improved stratification for ultra-high-risk disease.
THIS YEAR’S European Hematology Association (EHA) 2025 Congress spotlighted a transformative shift in the prognostic landscape of systemic light chain amyloidosis. Among more than 30 abstracts showcased, two studies stood out: one redefining ultra-high-risk cardiac disease through the Mayo Stage IIIc model, and another introducing circulating tumour cells as a non-invasive biomarker with independent prognostic value. Together, they delivered a clear message: in AL amyloidosis, the future of risk stratification lies at the intersection of refined cardiac imaging and cellular precision.
No takes yet. Share an insight, caveat, or question.
Selin Küçükyurt (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: